ArticleArchives of rheumatology2025
Evaluation of adipokines, oxidative stress, and inflammatory markers in gout patients.
Article in Archives of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to investigate the role of adipokines, oxidative stress, and inflammatory markers in the pathogenesis of gout. Patients and methods: Between September 2021 and December 2022, a total of 88 volunteers including 44 patients (37 males, 7 females; mean age: 56.5±11.6 years; range, 30 to 77 years) with gout disease and 44 age- and sex-matched healthy controls (37 males, 7 females; mean age: 54.3±12.1 years; range, 30 to 78 years) were retrospectively analyzed. Serum interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), irisin, resistin, total oxidant status (TOS), and total antioxidant status (TAS) levels were analyzed. Results: The mean serum irisin levels were significantly higher in patients with gout than in the healthy controls (405.6±97.3 and 316.0±80.8 pg/mL, respectively). The mean IL-10 levels were significantly lower in patients with gout than in healthy controls (90.8±71.9 and 172.7±128.6 pg/mL, respectively). There was no statistically significant difference in the serum resistin, TNF-α, TOS, or TAS levels between the groups (p>0.05). Conclusion: Our study results show that serum irisin and IL-10 seem to be candidate biomarkers of diagnosis of gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.